{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-2770"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-2770","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Prenatal buprenorphine exposure reduces expression of myelin proteins in neonatal longs-Evans rat","abstract":"In the USA and especially in WV, there has been a surge in the rise of opioid use disorder (OUD), and with it a rise in neonatal abstinence syndrome (NAS). What makes this rise in NAS so unfortunate is that the Medications for OUD (MOUD) do not prevent the development of NAS. Although the relationship between MOUD and NAS is still unclear, it is thought that buprenorphine, one of the main substances used to treat OUD in pregnant women, may feed into the development of NAS, which may affect mental and physiological development and cause other health problems. Via understanding the developmental impact of NAS, we hope to pave the way for future NAS treatments and a brighter future for the children of the USA. The central hypothesis of this proposal is that developmental issues caused by prenatal buprenorphine exposure are due to reduced expression of white matter development proteins, such as NG2 and MBP, and changes in neuronal proteins such as Kif5A, and that these changes cause deficits in the white matter parts of the brain. To study this hypothesis, we used a rat in utero buprenorphine exposure model to investigate the impact of this opioid on the post-natal time course of protein expression in two white matter tracts, the optic nerve and cerebellum. Preliminary Western blot analysis indicates that there is a significant interaction between post-natal age and treatment for multiple proteins involved in myelination. Both white matter tracks also showed significant increases of KiF5A late in post-natal development. This data indicates that in utero buprenorphine impacts white matter development promoting a change in the protein expression timelines. If these developmental changes are maintained throughout the life span, they could explain some of the issues associated with the long-term impact of NAS.","abstract_html":"In the USA and especially in WV, there has been a surge in the rise of opioid use disorder (OUD), and with it a rise in neonatal abstinence syndrome (NAS). What makes this rise in NAS so unfortunate is that the Medications for OUD (MOUD) do not prevent the development of NAS. Although the relationship between MOUD and NAS is still unclear, it is thought that buprenorphine, one of the main substances used to treat OUD in pregnant women, may feed into the development of NAS, which may affect mental and physiological development and cause other health problems. Via understanding the developmental impact of NAS, we hope to pave the way for future NAS treatments and a brighter future for the children of the USA. The central hypothesis of this proposal is that developmental issues caused by prenatal buprenorphine exposure are due to reduced expression of white matter development proteins, such as NG2 and MBP, and changes in neuronal proteins such as Kif5A, and that these changes cause deficits in the white matter parts of the brain. To study this hypothesis, we used a rat in utero buprenorphine exposure model to investigate the impact of this opioid on the post-natal time course of protein expression in two white matter tracts, the optic nerve and cerebellum. Preliminary Western blot analysis indicates that there is a significant interaction between post-natal age and treatment for multiple proteins involved in myelination. Both white matter tracks also showed significant increases of KiF5A late in post-natal development. This data indicates that in utero buprenorphine impacts white matter development promoting a change in the protein expression timelines. If these developmental changes are maintained throughout the life span, they could explain some of the issues associated with the long-term impact of NAS.","abstract_has_math":false,"creators":["Grahe, Christopher James"],"institution":null,"degree_name":"Biomedical Sciences","degree_level":"Thesis","degree_discipline":"Joan C. Edwards School of Medicine","degree_department":null,"school":null,"contributors":["Dr. Larry Grover, Committee Chair","Dr. Richard Egleton","Dr. Travis Salisbury"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:58:01Z","subjects":["Chemicals and Drugs","Medical Pharmacology","Medical Sciences","Medical Toxicology","Medicine and Health Sciences","Other Chemicals and Drugs","Brain","Buprenorphine","Development"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/1765","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/1765","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-2770","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Larry Grover, Committee Chair","Dr. Richard Egleton","Dr. Travis Salisbury"]},{"key":"dc:creator","label":"Author","values":["Grahe, Christopher James"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2023-04-26T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2023-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Joan C. Edwards School of Medicine"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Biomedical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemicals and Drugs","Medical Pharmacology","Medical Sciences","Medical Toxicology","Medicine and Health Sciences","Other Chemicals and Drugs","Brain","Buprenorphine","Development"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/1765"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["In the USA and especially in WV, there has been a surge in the rise of opioid use disorder (OUD), and with it a rise in neonatal abstinence syndrome (NAS). What makes this rise in NAS so unfortunate is that the Medications for OUD (MOUD) do not prevent the development of NAS. Although the relationship between MOUD and NAS is still unclear, it is thought that buprenorphine, one of the main substances used to treat OUD in pregnant women, may feed into the development of NAS, which may affect mental and physiological development and cause other health problems. Via understanding the developmental impact of NAS, we hope to pave the way for future NAS treatments and a brighter future for the children of the USA. The central hypothesis of this proposal is that developmental issues caused by prenatal buprenorphine exposure are due to reduced expression of white matter development proteins, such as NG2 and MBP, and changes in neuronal proteins such as Kif5A, and that these changes cause deficits in the white matter parts of the brain. To study this hypothesis, we used a rat in utero buprenorphine exposure model to investigate the impact of this opioid on the post-natal time course of protein expression in two white matter tracts, the optic nerve and cerebellum. Preliminary Western blot analysis indicates that there is a significant interaction between post-natal age and treatment for multiple proteins involved in myelination. Both white matter tracks also showed significant increases of KiF5A late in post-natal development. This data indicates that in utero buprenorphine impacts white matter development promoting a change in the protein expression timelines. If these developmental changes are maintained throughout the life span, they could explain some of the issues associated with the long-term impact of NAS."]},{"key":"dc:title","label":"Title","values":["Prenatal buprenorphine exposure reduces expression of myelin proteins in neonatal longs-Evans rat"]}]}],"canonical_facts":{"dc:contributor":["Dr. Larry Grover, Committee Chair","Dr. Richard Egleton","Dr. Travis Salisbury"],"dc:creator":["Grahe, Christopher James"],"dc:date.available":["2023-04-26T07:00:00Z"],"dc:date.created":["2023-01-01T08:00:00Z"],"dc:description.abstract":["In the USA and especially in WV, there has been a surge in the rise of opioid use disorder (OUD), and with it a rise in neonatal abstinence syndrome (NAS). What makes this rise in NAS so unfortunate is that the Medications for OUD (MOUD) do not prevent the development of NAS. Although the relationship between MOUD and NAS is still unclear, it is thought that buprenorphine, one of the main substances used to treat OUD in pregnant women, may feed into the development of NAS, which may affect mental and physiological development and cause other health problems. Via understanding the developmental impact of NAS, we hope to pave the way for future NAS treatments and a brighter future for the children of the USA. The central hypothesis of this proposal is that developmental issues caused by prenatal buprenorphine exposure are due to reduced expression of white matter development proteins, such as NG2 and MBP, and changes in neuronal proteins such as Kif5A, and that these changes cause deficits in the white matter parts of the brain. To study this hypothesis, we used a rat in utero buprenorphine exposure model to investigate the impact of this opioid on the post-natal time course of protein expression in two white matter tracts, the optic nerve and cerebellum. Preliminary Western blot analysis indicates that there is a significant interaction between post-natal age and treatment for multiple proteins involved in myelination. Both white matter tracks also showed significant increases of KiF5A late in post-natal development. This data indicates that in utero buprenorphine impacts white matter development promoting a change in the protein expression timelines. If these developmental changes are maintained throughout the life span, they could explain some of the issues associated with the long-term impact of NAS."],"dc:identifier":["https://mds.marshall.edu/etd/1765"],"dc:subject":["Chemicals and Drugs","Medical Pharmacology","Medical Sciences","Medical Toxicology","Medicine and Health Sciences","Other Chemicals and Drugs","Brain","Buprenorphine","Development"],"dc:title":["Prenatal buprenorphine exposure reduces expression of myelin proteins in neonatal longs-Evans rat"],"thesis:degree_discipline":["Joan C. Edwards School of Medicine"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Biomedical Sciences"]},"updated_at":"2026-11-21T19:58:01Z"}